Physician profile
David Bryant
NPI 1124000435
$15,016.70
in general payments reported to CMS, 2019-2025
81 companies · $2,483 in 2025
The $2,483 reported for 2025 was more than what 91% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,480 · 2020: $1,456 · 2021: $1,451 · 2022: $1,200 · 2023: $1,483 · 2024: $2,464 · 2025: $2,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,429.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accuray Incorporated | $1,596.02 | 2019-2025 | Tomo Therapy System, Cyberknife System |
| Astrazeneca Pharmaceuticals Lp | $1,219.53 | 2019-2025 | Tagrisso, Datroway, Imfinzi |
| Abbvie INC. | $859.19 | 2019-2025 | Venclexta |
| Eisai INC. | $641.68 | 2019-2025 | |
| Janssen Biotech, INC. | $635.32 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Regeneron Healthcare Solutions, INC. | $554.52 | 2019-2025 | Libtayo, Lynozyfic |
| Amgen INC. | $535.60 | 2019-2023 | Kyprolis, Blincyto |
| Novocure INC. | $474.97 | 2023-2025 | Optune, Optune Lua (Novottf-200t) |
| Novartis Pharmaceuticals Corporation | $465.45 | 2019-2025 | |
| Tersera Therapeutics LLC | $461.91 | 2019-2025 | Zoladex, Xermelo, Quzyttir |
| Seagen INC. | $386.36 | 2019-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $367.12 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $337.23 | 2019-2025 | Phesgo, Itovebi, Polivy |
| Puma Biotechnology, INC. | $323.29 | 2019-2021 | |
| Genzyme Corporation | $293.41 | 2019-2025 |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.